For type 2 diabetes mellitus. ANDA 213359, held by Unichem. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 213359 (Metformin Hydrochloride), held by Unichem, was first approved by FDA on Aug 11, 2021, with 1 approved supplement and 0 published complete response letters.
Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 11, 2021 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride750MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 11, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters